Approaches to Identifying Clinically Significant SNPs in Cancer Research

Abstract

Single nucleotide polymorphisms (SNPs) are single-base alterations (purine or pyrimidine) at specific DNA nucleotide. Unlike mutations, SNPs are generally defined as common germline variants present in at least 1% of the population. They are important targets in numerous clinical applications, including the assessment of disease susceptibility, the diagnostic and prognostic biomarkers, and the prediction of therapeutic response. Clinically significant SNPs located within coding regions may alter protein structure or function, whereas those in promoter regions can influence gene expression. The identification of clinically relevant SNPs in cancer involves a range of bioinformatic approaches, including database mining, literature review, and, where appropriate, experimental validation. Depending on the research objective, several public databases provide information on SNP location and functional annotation. For example, dbSNP, maintained by the National Center for Biotechnology Information (NCBI), is a widely used repository of genetic variation. ClinVar is an archive of genomic variants and their relationships to disease, including evidence regarding drug response; however, its data are intended for research rather than diagnostic use. The GWAS Catalog contains thousands of publications and tens of thousands of SNP–trait associations. OMIM (Online Mendelian Inheritance in Man) catalogs variants associated with Mendelian disorders across more than 16,000 genes and is a valuable resource for genotype–phenotype correlations. The 1000 Genomes Project provides comprehensive data on SNPs and structural variants across diverse populations, generated with high-throughput sequencing technologies. Bioinformatic tools such as SIFT, PolyPhen-2, GTEx, and FASTSNP are commonly used to predict the functional impact of novel SNPs. Confirmation of clinical significance typically requires experimental validation, including PCR-based genotyping methods (e.g., TaqMan assays or high-resolution melting analysis), next-generation sequencing, and functional assays to assess effects on protein activity. All in all, these resources and approaches form a robust framework for identifying clinically significant SNPs in cancer research.